Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: lenalidomide (Revlimid®)
Drug: Cyclophosphamide
Drug: Prednisone

First Posted Date: 2007-10-08

Last Posted Date: 2016-06-21

Lead Sponsor: Attaya Suvannasankha

Target Recruit Count: 70

Registration Number: NCT00540644

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Lymphoma
Leukemia

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: pentostatin

First Posted Date: 2007-10-08

Last Posted Date: 2017-08-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 49

Registration Number: NCT00541034

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer

Interventions: Drug: cyclophosphamide
Drug: celecoxib

First Posted Date: 2007-10-02

Last Posted Date: 2023-04-21

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 52

Registration Number: NCT00538031

Locations: 🇺🇸
City of Hope Medical Group Inc, Pasadena, California, United States
🇺🇸
City of Hope, Duarte, California, United States

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Not Applicable

Completed

Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Childhood Acute Lymphoblastic Leukemia in Remission

Interventions: Drug: cyclophosphamide
Drug: etoposide
Drug: melphalan
Drug: busulfan
Radiation: total-body irradiation
Drug: carboplatin
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Drug: carmustine
Drug: thiotepa
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2007-09-28

Last Posted Date: 2021-04-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 174

Registration Number: NCT00536601

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Drug: ARA-C
Drug: BCNU
Drug: Campath-1H
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Fludarabine
Drug: Melphalan
Drug: Rituximab
Other: Allogeneic Stem Cell Transplantation
Radiation: Total body radiation (TBI)
Drug: Methotrexate
Drug: Tacrolimus
Procedure: Adback NK or T Cell

First Posted Date: 2007-09-28

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT00536978

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

Phase 2

Conditions: Breast Cancer

First Posted Date: 2007-09-24

Last Posted Date: 2013-08-26

Lead Sponsor: Instituto Nacional de Cancerologia, Columbia

Target Recruit Count: 160

Registration Number: NCT00533936

Locations: 🇲🇽
Instituto Nacional de Cancerologia, Mexico City, Distrito Federal, Mexico
🇲🇽
Hospital General de Mexico, Mexico City, Distrito Federal, Mexico

LAL-BR/2001: Study Treatment to Low Risk ALL

Phase 4

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2007-09-10

Last Posted Date: 2016-01-20

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 150

Registration Number: NCT00526175

Locations: 🇪🇸
Basurtuko Ospitalea, Basurto, Spain
🇪🇸
Complejo Hospitalario Universitario de Albacete, Albacete, Spain
🇪🇸
Hospital General de Alicante, Alicante, Spain

and more 22 locations

Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

Not Applicable

Conditions: Neuroblastoma

First Posted Date: 2007-09-10

Last Posted Date: 2015-07-16

Lead Sponsor: German Society for Pediatric Oncology and Hematology GPOH gGmbH

Target Recruit Count: 360

Registration Number: NCT00526318

Locations: 🇩🇪
Klinikum Augsburg, Augsburg, Germany
🇩🇪
Evangelisches Krankenhauus Bielfeld, Biefeld, Germany
🇩🇪
Klinikum Duisburg, Duisburg, Germany

and more 64 locations

LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia

Phase 4

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2007-09-10

Last Posted Date: 2014-10-28

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 40

Registration Number: NCT00526409

Locations: 🇪🇸
Hospital Niño Jesús, Madrid, Spain
🇪🇸
Hospital materno Infantil vall d'Hebrón, Barcelona, Spain
🇪🇸
Hospital Infantil Carlos Haya, Málaga, Spain

and more 1 locations

Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Biological: natural killer cell therapy
Drug: cyclophosphamide
Drug: fludarabine

First Posted Date: 2007-09-10

Last Posted Date: 2016-02-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT00526292

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy